Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Park West Asset Management and Eagle Pharmaceuticals, Inc. (EGRX)

Page 1 of 9

Peter Park‘s Park West Asset Management has recently reported its position in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) through a 13G filing with the Securities and Exchange Commission. According to the filing, Park West owns 690,000 shares of Eagle Pharmaceutical and the stake, which is passive by nature, amasses 4.4% of the company’s outstanding common stock.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Park West Asset Management LLC 690,000 0 690,000 0 690,000 4.4%
Peter S. Park 690,000 0 690,000 0 690,000 4.4%
Peter S. Park
Peter S. Park
Park West Asset Management

Page 1 of 9 SEC Filing

Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
(Name of Issuer)
(Title of Class of Securities)
(CUSIP Number)
December 31, 2015
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
o  Rule 13d-1(b)
x Rule 13d-1(c)
o  Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
Trade (NASDAQ:EGRX) Now!
Page 1 of 9